Liviu Niculescu, MD PhD, Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate at Annual Meeting 2018
Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate
Liviu Niculescu, MD PhD, Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate at Annual Meeting 2018